

Immunotherapy
ADCC
Therapeutic-Antibody-Assay
BsAbs CDC
ADC
Immuno-Oncology


TissueScreen

The tissue-based approach to target relevant proteins



Many development in the field of antibody-based therapies are lately confronted with failure situations due to misidentification of the target of interest.

We offer a realistic approach and without any a priori to define the best target protein signature of a pathology.

By identifying a previously unseen target on a given pathology, industrial property protection strategies are more effective !



What we offer





What makes us different?

●●● TissueScreen is an approach based on tissue analysis not on cell model

Classical approach on cell model	TissueScreen
Need to validate the relevance of a cell line	<u>Targeted</u> tissues collections allowing access to a <u>variety of real cases</u>
Physiological cell culture environment missing	Physiological environment in the frozen available tissue samples
Influence of culture conditions	Unmodified (frozen) samples preservation

●●● TissueScreen is an integrated process, from the biopsy up to the the targets validation.

Why waiting for advanced developments to use a tissue model ?



PHYLOGENE



Who are we ?

HISTALIM

Histalim, the **European leading company** in the field of histopathology, have been providing **for ten years** R&D services in histology, Immuno Histo Chemistry (IHC), *In Situ* Hybridization (ISH) and morphometry to pharmas and biotech companies.

PHYLOGENE is a **Multi-Omics services company** with a broad expertise in **High Resolution Mass Spectrometry Proteomics**. Their untargeted approach is based on unique **CORAVALID™** bioinformatic tools.

Through **TissueScreen**, HISTALIM and PHYLOGENE combines the **tissue analysis** reliability to the **genomics** and **proteomics** tools.

#Immunohistochemistry #In Situ Hybridization #Morphometry

#High resolution mass Spectrometry #BioInformatics #Proteomics

